Legal&Gen UCITS ETF

Updates to Prospectus Documentation & Constitution

RNS Number : 2116K
Legal & General UCITS ETF PLC
20 April 2020
 

20 April 2020

 

LEGAL & GENERAL UCITS ETF PLC

 

(the "Company")

 

Updates to the Company's Prospectus Documentation and Constitution

Following the announcement on the 31st March 2020 in respect of the appointment of LGIM Managers (Europe) Limited as manager of the Company (the "Rationalisation") and the announcement earlier today in respect of the Company's change of share settlement structure (the "ICSD Transition"), the Company confirms that its prospectus, fund supplements and fund schedule supplement (the "Prospectus Documentation") have been approved by the Central Bank of Ireland (the "CBI") as of today's date.

The Prospectus was updated to reflect the Rationalisation and the ICSD Transition , as well as other passage of time updates.

 

The constitution of the Company (the "Constitution") has also been updated to reflect the ICSD Transition. The Constitution has been approved by the CBI and is effective as of today's date.

 

The revised Prospectus Documentation and Constitution will be made available shortly at:

 

• https://www.lgimetf.com;

• the office of LGIM Managers (Europe) Limited at 33/34 Sir John Rogerson's Quay, Dublin 2; and

• the offices of the relevant paying and information agents for each country in which the sub-funds of the Company have been registered for public distribution.

 

A copy of the revised documentation has been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism

   

 

Further information:

 

Legal & General Investment Management Limited

Tel: 0345 070 8684

Email: [email protected]

 

J&E Davy (Sponsor) 

Fergal Meegan / Brian Garrahy  + 353 1 6796363

 

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
PDIEAELEALPEEFA